文献速递垂体与肾上腺疾病

关于糖皮质激素减量及下丘脑-垂体-肾上腺轴恢复的回顾性研究

A Retrospective Study on Weaning Glucocorticoids and Recovery of the Hypothalamic-Pituitary-Adrenal Axis.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

该回顾性队列研究纳入2015至2022年门诊长期使用泼尼松龙并接受HPA轴检测的患者,评估减量过程中HPA轴恢复率,并比较转换为氢化可的松后的结局。泼尼松龙组总体恢复率为66.5%(137/206),剂量匹配亚组中泼尼松龙组恢复率70%(7/10)高于氢化可的松转换组15%(2/13)(P=.008)。作者认为每日一次泼尼松龙减量即可恢复HPA轴功能,转换为多次给药氢化可的松无明显优势。

要点

  • 长期泼尼松龙患者减量后HPA轴恢复率为66.5%(137/206)。
  • 剂量匹配亚组中泼尼松龙组恢复率70%(7/10)高于氢化可的松组15%(2/13)(P=.008)。
  • 作者认为转换为多次给药氢化可的松对HPA轴恢复无明显优势。

核心结论

  • 糖皮质激素诱导的肾上腺功能不全患者维持每日一次泼尼松龙减量可恢复HPA轴功能,转换为多次给药氢化可的松无明显优势。

研究设计与样本

  • 回顾性队列研究,地点为门诊内分泌类固醇诊所,纳入2015至2022年长期使用泼尼松龙并转诊进行HPA轴检测的患者,共206例。

主要发现

  • 泼尼松龙组间隔检测后总体HPA轴恢复率为137/206(66.5%)。
  • 剂量匹配的泼尼松龙组与氢化可的松转换组HPA轴恢复率分别为7/10(70%)和2/13(15%)(P=.008)。
  • 剂量匹配两组平均(SD)年龄67.1(12.2)岁 vs 63.4(11.1)岁(P=.464),基线皮质醇5.3(4.2)µg/dL vs 4.6(3.1)µg/dL(P=.648),糖皮质激素使用时间中位数[IQR]1213[1114]天 vs 2316[4808]天(P=.693),基线ACTH中位数[IQR]20.5[29.0]ng/L vs 16.3[14.8]ng/L(P=.905),均无显著差异。
  • 泼尼松龙组随访时间中位数[IQR]348[975]天,显著低于氢化可的松转换组的667[884]天(P=.012)。

临床怎么用

  • 作者认为,糖皮质激素诱导的肾上腺功能不全患者维持每日一次泼尼松龙减量即可恢复HPA轴功能,转换为多次给药氢化可的松对HPA轴恢复无明显优势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Glucocorticoids suppress the hypothalamic-pituitary-adrenal (HPA) axis, resulting in tertiary adrenal insufficiency (AI). When weaning patients off glucocorticoids there is no consensus on whether to maintain patients on prednisolone or convert to hydrocortisone. OBJECTIVE: To investigate HPA axis recovery in patients on long-term prednisolone and assess outcome after hydrocortisone conversion. METHODS: This was a retrospective cohort study at an outpatient endocrine steroid clinic. Patients were on long-term prednisolone and referred for HPA axis testing between 2015 and 2022. The main outcomes measured were (1) HPA axis recovery rate in patients on prednisolone demonstrated by a normal adrenocorticotrophic hormone (ACTH) stimulation test (AST) and (2) HPA axis recovery rate subanalysis of dose-matched patients with confirmed tertiary AI on prednisolone or hydrocortisone were measured. RESULTS: In total, 206 patients on prednisolone were tested for tertiary AI. Of these, 176 remained on prednisolone while 30 were converted to hydrocortisone. The overall HPA axis recovery rate for patients on prednisolone after interval testing was 137/206 (66.5%). The HPA axis recovery rate in dose-matched prednisolone and hydrocortisone conversion groups was 7/10 (70%) and 2/13 (15%) (P = .008), respectively. There was no difference in mean (SD) age (67.1 [12.2] vs 63.4 [11.1] years; P = .464) and baseline cortisol (5.3 [4.2] vs 4.6 [3.1] µg/dL; P = .648) and median [interquartile, IQR] glucocorticoid duration (1213 [1114] vs 2316 [4808] days; P = .693) and baseline ACTH (20.5 [29.0] vs 16.3 [14.8] ng/L; P = .905) between dose-matched prednisolone and hydrocortisone groups. Follow-up duration in the prednisolone group was significantly lower (median [IQR] 348 [975] vs 667 [884] days; P = .012). CONCLUSION: Patients with glucocorticoid-induced AI maintained on once-daily prednisolone can recover HPA axis function when weaning. There is no apparent advantage to recover HPA axis function in converting to multiple-dosing hydrocortisone.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Arshad MF, Elder C, Newell-Price J, et al. A Retrospective Study on Weaning Glucocorticoids and Recovery of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab. 2024. PMID: 38298131. doi:10.1210/clinem/dgae059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。